Multiple sclerosis (MS) is a condition that disrupts the information pathways that connect your brain and your body. From time to time, the symptoms of MS can unexpectedly worsen. When symptoms ...

Please provide your email address to receive an email when new articles are posted on . Data were analyzed from 709 participants given ozanimod or interferon in two different trials trials. At 6 ...

"The observed differential effects of high-efficacy disease-modifying agents across sexes underscore the importance of sex-specific considerations in making treatment decisions to personalize care in ...

“Our data add and expand previous observations on silent progression in MS and are consistent with the view of the disease as a single continuum, in which RAW [relapse-associated worsening] and PIRA ...

(Barcelona, Spain, Wednesday, 24 September 2025) New research presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2025) demonstrates that ...

Please provide your email address to receive an email when new articles are posted on . Chart review yielded 38 persons with MS and cancer treated with immune checkpoint inhibitors. Thirteen patients ...

A blood test that measures elevations in neurofilament light chain (NfL) levels in patients with multiple sclerosis (MS) could warn of worsening disability up to 2 years before it occurs, a new study ...

Relapsing-remitting multiple sclerosis (MS) is commonly treated with parenteral drugs that can lead to adverse events and poor adherence. Three phase 3 randomized trials evaluated the efficacy and ...

Mavenclad (cladribine) is a medicine used to treat relapsing forms of multiple sclerosis (MS) including relapsing-remitting MS and active secondary progressive MS. Relapsing forms of MS have temporary ...

Women with multiple sclerosis (MS) can have children, breastfeed, and resume disease-modifying treatment (DMT) without experiencing an increased risk of relapse during the postpartum period, according ...